Thermo Fisher Scientific Releases 2022 Corporate Social Responsibility Report

 

  Company highlights colleagues' commitment to innovation, progress toward   ambitious targets, and building a brighter future for all stakeholders  

 

Thermo Fisher Scientific Inc. (NYSE: TMO), the world leader in serving science, today released its annual Corporate Social Responsibility (CSR) report. The report highlights the company's commitment to society and stakeholders and provides insight into its CSR progress and environmental, social and governance (ESG) efforts.

 

"Our Mission to enable our customers to make the world healthier, cleaner and safer inspires our 125,000 colleagues every day. We are proud of the progress we are making across our CSR commitments and ESG priorities and we're excited about the opportunities ahead to continue making a positive impact."

 

Thermo Fisher's CSR report centers on four key pillars—Environment, Colleagues, Communities, and Operations—aligned to the company's strategy and values; and showcases the innovation made possible by the passion and talent of its more than 125,000 colleagues worldwide. Highlights of the report include:

 

  Environment  

 
  • Progressed the company's net-zero emissions goals—approved by the Science Based Targets initiative (SBTi)—for Scopes 1, 2 and 3; achieving a 25% reduction in Scopes 1 and 2 compared to 2018; reaching fossil fuel-free status at 20 sites; and powering 150 sites with renewable electricity.
  •  
  • Expanded its Design for Sustainability program to accelerate the integration of environmental considerations in product innovation, furthering a long-standing colleague-driven commitment to deliver new solutions that help customers reach their business and sustainability goals.
  •  
  • Delivered on the company's commitment to climate and nature by introducing near-term targets aimed at addressing water scarcity and reducing waste.
  •  

  Colleagues  

 
  • Increased global representation of women in the company's workforce by 5.9% since 2019, including a 9.3% increase of U.S. women in executive management roles.
  •  
  • Provided additional support to meet colleagues' evolving needs, including making special payments to offset the global impact of inflation, and expanding mental health coverage in the U.S. by implementing a Behavioral Health Navigator platform.
  •  

  Communities  

 
  • Reached more than 89,500 students through global programming to advance STEM education access and equity, completed a record number of community engagement events resulting in over 120,000 colleague volunteer hours, and launched the Thermo Fisher Scientific Junior Innovators Challenge, the premier middle school STEM competition in the U.S.
  •  
  • Advanced global health equity in more than 100 low- and middle-income countries and developed public-private partnerships to save more lives by making a positive impact in the management of infectious diseases like HIV/AIDS.
  •  

  Operations  

 
  • Optimized the company's responsible sourcing program to increase value to customers, assessing 50% of its direct materials supply for ESG performance and granting over $2 billion in awards to small and diverse suppliers.
  •  

In reporting its CSR progress, the company considers internationally recognized standards, guidelines and reference frameworks including the Global Reporting Initiative (GRI) Standards, the IFRS Foundation's SASB Standards, the Task Force on Climate-related Financial Disclosures (TCFD), and the United Nations Sustainable Development Goals (SDGs). The company makes additional topic-specific ESG data available to key stakeholders through CDP, EcoVadis and the voluntary disclosure of its annual EEO-1 information.

 

Learn more at www.thermofisher.com/csr .

 

  About Thermo Fisher Scientific  

 

Thermo Fisher Scientific Inc. is the world leader in serving science, with annual revenue over $40 billion. Our Mission is to enable our customers to make the world healthier, cleaner and safer. Whether our customers are accelerating life sciences research, solving complex analytical challenges, increasing productivity in their laboratories, improving patient health through diagnostics or the development and manufacture of life-changing therapies, we are here to support them. Our global team delivers an unrivaled combination of innovative technologies, purchasing convenience and pharmaceutical services through our industry-leading brands, including Thermo Scientific, Applied Biosystems, Invitrogen, Fisher Scientific, Unity Lab Services, Patheon and PPD. For more information, please visit www.thermofisher.com .

 

  

  

Media:
Sandy Pound
Thermo Fisher Scientific
Phone: 781-622-1223
E-mail: sandy.pound@thermofisher.com  

 

Investor:
Rafael Tejada
Thermo Fisher Scientific
Phone: 781-622-1356
E-mail: rafael.tejada@thermofisher.com  

 

News Provided by Business Wire via QuoteMedia

TMO
The Conversation (0)
illustration of brain and cell phone.

BlinkLab Completes First Patient Test for US Autism Diagnostic Study

Digital healthcare company BlinkLab (ASX:BB1) has tested the first patient in its US autism diagnostic study, which is geared at validating the company's Dx1 test as a diagnostic aid for clinicians.

BlinkLab states in its Wednesday (March 12) release that the study is the largest digital diagnostic trial for autism in the US, with its aim being to support the early detection of developmental conditions like autism.

The first patient test took place at PriMED Clinical Research in Dayton, Ohio. PriMED, a division of PriMED Physicians, is one of two clinical sites selected for the study’s initial phase, which is targeting 100 patients.

Keep reading...Show less
HeraMED Signs Strategic Collaboration Agreement with Garmin Health

HeraMED Signs Strategic Collaboration Agreement with Garmin Health

HeraMED Limited (ASX: HMD), a medical data and technology company leading the digital transformation of maternity care, is delighted to announce it has entered into a collaboration agreement with Garmin (NYSE: GRMN), a leading global provider of smartwatches and GPS-enabled products, aimed at enhancing remote pregnancy monitoring and expanding the range of health data available to expectant mothers and their healthcare providers.

Keep reading...Show less
Cardiologist wearing virtual reality glasses.

2 Biggest Medical Device ETFs in 2025

Exchange-traded funds (ETFs) are a popular investment strategy, and generally contain a variety of publicly traded companies under one stock symbol, often with a focus on a specific sector.

Depending on the ETF, investors may be able to track up-and-coming companies, get exposure to top firms or a mix of both. Aside from stocks, some ETFs also track commodities or bonds.

In the healthcare industry, medical device ETFs bring together companies that go to great lengths to develop pharmaceutical-based technology that can improve the lives of patients.

Keep reading...Show less
Cyclomedica

Cyclopharm Signs US Agreement with HCA Healthcare for Technegas®

Cyclopharm Limited (ASX: CYC) is pleased to announce the signing of a major contract with Hospital Corporation of America Healthcare (HCA), one of the largest single healthcare providers in the United States. This agreement marks a significant milestone for the company which will allow the deployment of Technegas® in up to 169 nuclear medicine departments across HCA’s extensive network.1

Keep reading...Show less
CONNEQT App Launches in USA as Pulse Deliveries Commence

CONNEQT App Launches in USA as Pulse Deliveries Commence

Cardiex Limited (CDX:AU) has announced CONNEQT App Launches in USA as Pulse Deliveries Commence

Download the PDF here.

Female doctor with clipboard talking to smiling female patient at hospital.

Revolutionizing Women's Health: Antifungal Innovation Brings New Investment Opportunities

The intersection of women's health and antifungal innovation represents a pivotal moment in healthcare, offering both transformative medical advancements and compelling investment opportunities.

The groundbreaking developments in antifungal treatments specifically targeting women's health issues present a substantial market potential, resulting in rising investor interest in this rapidly evolving sector.

Despite comprising half the global population, women face unique health challenges that have historically received insufficient attention and investment. Among these health challenges, vaginal candidiasis stands out as a persistent and widespread issue affecting millions of women worldwide.

Keep reading...Show less

Latest Press Releases

Related News

×